Pfizer, Summit Therapeutics and ivonescimab
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc.
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
1h
Summit Therapeutics Inc (SMMT) reports a robust cash reserve and debt-free status, while advancing key clinical trials and ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).
Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback